Dorsa to resign as Gilead CFO

FOSTER CITY, Calif. Gilead Sciences has announced that Caroline Dorsa has resigned from her position as chief financial officer, a role she assumed in November 2007.

Gilead plans to initiate a search to identify a new chief financial officer. In the interim, John Milligan, Gilead’s chief operating officer, will reassume the additional responsibilities of chief financial officer—a position he held from 2003 until 2007—effective immediately.

Gilead produces such products as the flu medication Tamiflu, the Hepatitis B treatment Hepsera and the HIV medication Emtriva.